| 28.67 -1.87 (-6.12%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.49 |
1-year : | 37.6 |
| Resists | First : | 29.52 |
Second : | 32.2 |
| Pivot price | 29.49 |
|||
| Supports | First : | 25.2 |
Second : | 20.97 |
| MAs | MA(5) : | 29.92 |
MA(20) : | 29.32  |
| MA(100) : | 28 |
MA(250) : | 20.16 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 54.7 |
D(3) : | 62.5 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 42.26 | Low : | 7.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RAPP ] has closed above bottom band by 23.2%. Bollinger Bands are 29.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 30.53 - 30.68 | 30.68 - 30.81 |
| Low: | 27.78 - 27.93 | 27.93 - 28.06 |
| Close: | 28.44 - 28.69 | 28.69 - 28.89 |
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Tue, 10 Mar 2026
Rapport Therapeutics: Advancing Precision Neuroscience with RAP Technology Platform for Neurological and Psychiatric Disorders 4048 - Minichart
Tue, 10 Mar 2026
Maintained Buy: RAPP analyst rating on Rapport Therapeutics, Inc. Common Stock Mar 2026 - Meyka
Wed, 04 Mar 2026
TD Asset Management Inc Has $4.07 Million Stock Holdings in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Wed, 18 Feb 2026
RAPP Stock Price and Chart — NASDAQ:RAPP - TradingView
Tue, 09 Sep 2025
Rapport says public offering of 9.6 million shares of its common stock at a price of $26.00 per share - marketscreener.com
Mon, 08 Sep 2025
Rapport: Surging On Phase 2 Study Win - Full Approval Unlikely Before 2028 (NASDAQ:RAPP) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 107.8 (%) |
| Shares Short | 3,400 (K) |
| Shares Short P.Month | 2,870 (K) |
| EPS | -2.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.9 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -12.63 |
| PEG Ratio | 0 |
| Price to Book value | 2.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|